Literature DB >> 31385203

Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline.

Simona Cintoli1,2, Claudia Radicchi1, Marianna Noale1, Stefania Maggi1, Giuseppe Meucci3, Gloria Tognoni4, Ubaldo Bonuccelli4, Alessandro Sale1, Nicoletta Berardi5, Lamberto Maffei1.   

Abstract

BACKGROUND AND AIMS: Cognitive impairments associated with aging and dementia are major sources of neuropsychiatric symptoms (NPs) and deterioration in quality of life (QoL). Preventive measures to both reduce disease and improve QoL in those affected are increasingly targeting individuals with mild cognitive impairment (MCI) at early disease stage. However, NPs and QoL outcomes are too commonly overlooked in intervention trials. The purpose of this study was to test the effects of physical and cognitive training on NPs and QoL in MCI.
METHODS: Baseline data from an MCI court (N = 93, mean age 74.9 ± 4.7) enrolled in the Train the Brain (TtB) study were collected. Subjects were randomized in two groups: a group participated to a cognitive and physical training program, while the other sticked to usual standard care. Both groups underwent a follow-up re-evaluation after 7 months from baseline. NPs were assessed using the Neuropsychiatric Inventory (NPI) and QoL was assessed using Quality of Life-Alzheimer's Disease (QOL-AD) scale.
RESULTS: After 7 months of training, training group exhibited a significant reduction of NPs and a significant increase in QOL-AD with respect to no-training group (p = 0.0155, p = 0.0013, respectively). Our preliminary results suggest that a combined training can reduce NPs and improve QoL.
CONCLUSIONS: Measuring QoL outcomes is a potentially important factor in ensuring that a person with cognitive deficits can 'live well' with pathology. Future data from non-pharmacological interventions, with a larger sample and a longer follow-up period, could confirm the results and the possible implications for such prevention strategies for early cognitive decline.

Entities:  

Keywords:  Mild cognitive impairment; Neuropsychiatric symptoms; Non-pharmacological interventions; Physical and cognitive training; Quality of life

Year:  2019        PMID: 31385203     DOI: 10.1007/s40520-019-01280-w

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  41 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis.

Authors:  Thomas D Koepsell; Sarah E Monsell
Journal:  Neurology       Date:  2012-09-26       Impact factor: 9.910

Review 4.  The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Authors:  Reisa Sperling; Elizabeth Mormino; Keith Johnson
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

Review 5.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

Review 6.  Is MCI really just early dementia? A systematic review of conversion studies.

Authors:  Maddalena Bruscoli; Simon Lovestone
Journal:  Int Psychogeriatr       Date:  2004-06       Impact factor: 3.878

Review 7.  Mild cognitive impairment: a systematic review.

Authors:  Elena Mariani; Roberto Monastero; Patrizia Mecocci
Journal:  J Alzheimers Dis       Date:  2007-08       Impact factor: 4.472

8.  Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease.

Authors:  Katie Palmer; Lars Bäckman; Bengt Winblad; Laura Fratiglioni
Journal:  Am J Geriatr Psychiatry       Date:  2008-07       Impact factor: 4.105

9.  Frequency and course of mild cognitive impairment in a multiethnic community.

Authors:  Jennifer J Manly; Ming-X Tang; Nicole Schupf; Yaakov Stern; Jean-Paul G Vonsattel; Richard Mayeux
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

Review 10.  Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature.

Authors:  Liana G Apostolova; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2007-12-14       Impact factor: 2.959

View more
  4 in total

1.  Randomized Trial on the Effects of a Group EMDR Intervention on Narrative Complexity and Specificity of Autobiographical Memories: A Path Analytic and Supervised Machine-Learning Study.

Authors:  Andrea Poli; Angelo Gemignani; Mario Miccoli
Journal:  Int J Environ Res Public Health       Date:  2022-06-23       Impact factor: 4.614

2.  How physical and motor training affect cognitive performance: lessons from an inflammatory molecule.

Authors:  Margherita Maffei; Marco Mainardi
Journal:  Neural Regen Res       Date:  2022-12       Impact factor: 6.058

Review 3.  Combined Motor and Cognitive Rehabilitation: The Impact on Motor Performance in Patients with Mild Cognitive Impairment. Systematic Review and Meta-Analysis.

Authors:  Pawel Kiper; Michelle Richard; Françoise Stefanutti; Romain Pierson-Poinsignon; Luisa Cacciante; Cecilia Perin; Miryam Mazzucchelli; Barbara Viganò; Roberto Meroni
Journal:  J Pers Med       Date:  2022-02-14

Review 4.  The role of enriched environment in neural development and repair.

Authors:  Yu Han; Mei Yuan; Yi-Sha Guo; Xin-Ya Shen; Zhen-Kun Gao; Xia Bi
Journal:  Front Cell Neurosci       Date:  2022-07-21       Impact factor: 6.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.